National Center for Personalized Medicine
Established in 2012, the Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM) is a state-of-the art research facility that provides Israeli academic, medical, and biomedical industry researchers with access to the most updated genomics, protein profiling, bioinformatics, drug discovery, and medicinal chemistry research platforms and know-how.
New Scientific Activities
Developing in-house automated protocols for RNA analysis for decreased cost and increased efficiency. Recently, The Weizmann Institute began implementing a protocol that enables researchers to assess the expression of genes in single cells. This protocol will facilitate the discovery of numerous genomic indicators of disease risk.
High-Throughput Screening (HTS)
The Compound Management Laboratory of the Maurice and Vivienne Wohl Institute for Drug Discovery recently completed the expansion of its compound library with the purchase of an additional 100,000 compounds. Compounds help ensure the Laboratory provides the best chemical materials for screening, to help identify “hits” through high-throughput screening (HTS).